Will Robinhood Win AI Investing?
Recently, online brokerage Robinhood (NASDAQ:HOOD) has been focused on introducing…
Sell
35
VIR Quote, Financials, Valuation and Earnings
Last price:
$6.51
Seasonality move
:
40.15%
Day range:
$6.21 - $6.83
52-week range:
$4.16 - $14.45
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
53.17x
P/B ratio:
1.14x
Volume:
1.9M
Avg. volume:
1.6M
1-year change:
-18.44%
Market cap:
$904.3M
Revenue:
$74.2M
EPS (TTM):
-$3.62
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
VIR
Vir Biotechnology, Inc.
|
$2M | -$0.86 | -88.55% | -17.61% | $17.22 |
|
BMY
Bristol Myers Squibb Co.
|
$10.5B | $1.49 | -0.74% | 4553.59% | $53.41 |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$3M | -$0.88 | 14.03% | -95.43% | $0.85 |
|
PTN
Palatin Technologies
|
-- | -$0.17 | -- | -67.93% | -- |
|
TOVX
Theriva Biologics, Inc.
|
-- | -$0.38 | -- | -94.42% | $7.00 |
|
VTGN
Vistagen Therapeutics, Inc.
|
$145.8K | -$0.44 | -6.58% | -18.27% | $14.50 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
VIR
Vir Biotechnology, Inc.
|
$6.50 | $17.22 | $904.3M | -- | $0.00 | 0% | 53.17x |
|
BMY
Bristol Myers Squibb Co.
|
$52.15 | $53.41 | $106.2B | 17.61x | $0.62 | 4.76% | 2.21x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$1.21 | $0.85 | $152.5M | 2.03x | $0.80 | 0% | 2.35x |
|
PTN
Palatin Technologies
|
$0.09 | -- | $2.4M | -- | $0.00 | 0% | -- |
|
TOVX
Theriva Biologics, Inc.
|
$0.23 | $7.00 | $7.6M | -- | $0.00 | 0% | 0.33x |
|
VTGN
Vistagen Therapeutics, Inc.
|
$4.33 | $14.50 | $171M | -- | $0.00 | 0% | 151.98x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
VIR
Vir Biotechnology, Inc.
|
11.18% | 2.054 | 12.62% | 6.76x |
|
BMY
Bristol Myers Squibb Co.
|
73.34% | -0.073 | 56.92% | 0.94x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
37.25% | 2.113 | 8.08% | 1.85x |
|
PTN
Palatin Technologies
|
-- | 1.358 | -- | -- |
|
TOVX
Theriva Biologics, Inc.
|
29.07% | -3.365 | 66.16% | 0.68x |
|
VTGN
Vistagen Therapeutics, Inc.
|
2.73% | 0.724 | 1.35% | 5.66x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
VIR
Vir Biotechnology, Inc.
|
-$2.7M | -$172.9M | -43.92% | -48.24% | -72034.58% | -$167.9M |
|
BMY
Bristol Myers Squibb Co.
|
$8.1B | $3.8B | 8.82% | 34.7% | 31.46% | $6B |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$42K | -$1.2M | -208.55% | -306.03% | -224.38% | -$1.8M |
|
PTN
Palatin Technologies
|
-- | -- | -- | -- | -- | -- |
|
TOVX
Theriva Biologics, Inc.
|
-$28K | -$4.4M | -148.18% | -171.04% | -- | -$4.3M |
|
VTGN
Vistagen Therapeutics, Inc.
|
$73K | -$20.1M | -74.76% | -76.57% | -7772.48% | -$13.8M |
Vir Biotechnology, Inc. vs. Competitors
-
Which has Higher Returns VIR or BMY?
Bristol Myers Squibb Co. has a net margin of -67975.42% compared to Vir Biotechnology, Inc.'s net margin of 17.96%. Vir Biotechnology, Inc.'s return on equity of -48.24% beat Bristol Myers Squibb Co.'s return on equity of 34.7%.
Company Gross Margin Earnings Per Share Invested Capital VIRVir Biotechnology, Inc.-1144.58% -$1.17 $896.3M BMYBristol Myers Squibb Co.66% $1.08 $69.6B -
What do Analysts Say About VIR or BMY?
Vir Biotechnology, Inc. has a consensus price target of $17.22, signalling upside risk potential of 164.96%. On the other hand Bristol Myers Squibb Co. has an analysts' consensus of $53.41 which suggests that it could grow by 2.41%. Given that Vir Biotechnology, Inc. has higher upside potential than Bristol Myers Squibb Co., analysts believe Vir Biotechnology, Inc. is more attractive than Bristol Myers Squibb Co..
Company Buy Ratings Hold Ratings Sell Ratings VIRVir Biotechnology, Inc.5 0 0 BMYBristol Myers Squibb Co.3 20 1 -
Is VIR or BMY More Risky?
Vir Biotechnology, Inc. has a beta of 1.346, which suggesting that the stock is 34.595% more volatile than S&P 500. In comparison Bristol Myers Squibb Co. has a beta of 0.296, suggesting its less volatile than the S&P 500 by 70.363%.
-
Which is a Better Dividend Stock VIR or BMY?
Vir Biotechnology, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Bristol Myers Squibb Co. offers a yield of 4.76% to investors and pays a quarterly dividend of $0.62 per share. Vir Biotechnology, Inc. pays -- of its earnings as a dividend. Bristol Myers Squibb Co. pays out 54.44% of its earnings as a dividend. Bristol Myers Squibb Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios VIR or BMY?
Vir Biotechnology, Inc. quarterly revenues are $240K, which are smaller than Bristol Myers Squibb Co. quarterly revenues of $12.2B. Vir Biotechnology, Inc.'s net income of -$163.1M is lower than Bristol Myers Squibb Co.'s net income of $2.2B. Notably, Vir Biotechnology, Inc.'s price-to-earnings ratio is -- while Bristol Myers Squibb Co.'s PE ratio is 17.61x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vir Biotechnology, Inc. is 53.17x versus 2.21x for Bristol Myers Squibb Co.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income VIRVir Biotechnology, Inc.53.17x -- $240K -$163.1M BMYBristol Myers Squibb Co.2.21x 17.61x $12.2B $2.2B
-
Which has Higher Returns VIR or NBY?
NovaBay Pharmaceuticals, Inc. has a net margin of -67975.42% compared to Vir Biotechnology, Inc.'s net margin of -255.85%. Vir Biotechnology, Inc.'s return on equity of -48.24% beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.
Company Gross Margin Earnings Per Share Invested Capital VIRVir Biotechnology, Inc.-1144.58% -$1.17 $896.3M NBYNovaBay Pharmaceuticals, Inc.8.06% -$0.22 $2.6M -
What do Analysts Say About VIR or NBY?
Vir Biotechnology, Inc. has a consensus price target of $17.22, signalling upside risk potential of 164.96%. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -29.75%. Given that Vir Biotechnology, Inc. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe Vir Biotechnology, Inc. is more attractive than NovaBay Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings VIRVir Biotechnology, Inc.5 0 0 NBYNovaBay Pharmaceuticals, Inc.1 0 0 -
Is VIR or NBY More Risky?
Vir Biotechnology, Inc. has a beta of 1.346, which suggesting that the stock is 34.595% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.569, suggesting its less volatile than the S&P 500 by 43.103%.
-
Which is a Better Dividend Stock VIR or NBY?
Vir Biotechnology, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. Vir Biotechnology, Inc. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios VIR or NBY?
Vir Biotechnology, Inc. quarterly revenues are $240K, which are smaller than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. Vir Biotechnology, Inc.'s net income of -$163.1M is lower than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, Vir Biotechnology, Inc.'s price-to-earnings ratio is -- while NovaBay Pharmaceuticals, Inc.'s PE ratio is 2.03x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vir Biotechnology, Inc. is 53.17x versus 2.35x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income VIRVir Biotechnology, Inc.53.17x -- $240K -$163.1M NBYNovaBay Pharmaceuticals, Inc.2.35x 2.03x $521K -$1.3M
-
Which has Higher Returns VIR or PTN?
Palatin Technologies has a net margin of -67975.42% compared to Vir Biotechnology, Inc.'s net margin of --. Vir Biotechnology, Inc.'s return on equity of -48.24% beat Palatin Technologies's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital VIRVir Biotechnology, Inc.-1144.58% -$1.17 $896.3M PTNPalatin Technologies-- -- -- -
What do Analysts Say About VIR or PTN?
Vir Biotechnology, Inc. has a consensus price target of $17.22, signalling upside risk potential of 164.96%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 7338.9%. Given that Palatin Technologies has higher upside potential than Vir Biotechnology, Inc., analysts believe Palatin Technologies is more attractive than Vir Biotechnology, Inc..
Company Buy Ratings Hold Ratings Sell Ratings VIRVir Biotechnology, Inc.5 0 0 PTNPalatin Technologies0 0 0 -
Is VIR or PTN More Risky?
Vir Biotechnology, Inc. has a beta of 1.346, which suggesting that the stock is 34.595% more volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.939, suggesting its less volatile than the S&P 500 by 6.103%.
-
Which is a Better Dividend Stock VIR or PTN?
Vir Biotechnology, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Vir Biotechnology, Inc. pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios VIR or PTN?
Vir Biotechnology, Inc. quarterly revenues are $240K, which are larger than Palatin Technologies quarterly revenues of --. Vir Biotechnology, Inc.'s net income of -$163.1M is higher than Palatin Technologies's net income of --. Notably, Vir Biotechnology, Inc.'s price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vir Biotechnology, Inc. is 53.17x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income VIRVir Biotechnology, Inc.53.17x -- $240K -$163.1M PTNPalatin Technologies-- -- -- --
-
Which has Higher Returns VIR or TOVX?
Theriva Biologics, Inc. has a net margin of -67975.42% compared to Vir Biotechnology, Inc.'s net margin of --. Vir Biotechnology, Inc.'s return on equity of -48.24% beat Theriva Biologics, Inc.'s return on equity of -171.04%.
Company Gross Margin Earnings Per Share Invested Capital VIRVir Biotechnology, Inc.-1144.58% -$1.17 $896.3M TOVXTheriva Biologics, Inc.-- -$0.45 $9.5M -
What do Analysts Say About VIR or TOVX?
Vir Biotechnology, Inc. has a consensus price target of $17.22, signalling upside risk potential of 164.96%. On the other hand Theriva Biologics, Inc. has an analysts' consensus of $7.00 which suggests that it could grow by 3004.21%. Given that Theriva Biologics, Inc. has higher upside potential than Vir Biotechnology, Inc., analysts believe Theriva Biologics, Inc. is more attractive than Vir Biotechnology, Inc..
Company Buy Ratings Hold Ratings Sell Ratings VIRVir Biotechnology, Inc.5 0 0 TOVXTheriva Biologics, Inc.1 1 0 -
Is VIR or TOVX More Risky?
Vir Biotechnology, Inc. has a beta of 1.346, which suggesting that the stock is 34.595% more volatile than S&P 500. In comparison Theriva Biologics, Inc. has a beta of 0.342, suggesting its less volatile than the S&P 500 by 65.818%.
-
Which is a Better Dividend Stock VIR or TOVX?
Vir Biotechnology, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Vir Biotechnology, Inc. pays -- of its earnings as a dividend. Theriva Biologics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios VIR or TOVX?
Vir Biotechnology, Inc. quarterly revenues are $240K, which are larger than Theriva Biologics, Inc. quarterly revenues of --. Vir Biotechnology, Inc.'s net income of -$163.1M is lower than Theriva Biologics, Inc.'s net income of -$4.4M. Notably, Vir Biotechnology, Inc.'s price-to-earnings ratio is -- while Theriva Biologics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vir Biotechnology, Inc. is 53.17x versus 0.33x for Theriva Biologics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income VIRVir Biotechnology, Inc.53.17x -- $240K -$163.1M TOVXTheriva Biologics, Inc.0.33x -- -- -$4.4M
-
Which has Higher Returns VIR or VTGN?
Vistagen Therapeutics, Inc. has a net margin of -67975.42% compared to Vir Biotechnology, Inc.'s net margin of -7525.97%. Vir Biotechnology, Inc.'s return on equity of -48.24% beat Vistagen Therapeutics, Inc.'s return on equity of -76.57%.
Company Gross Margin Earnings Per Share Invested Capital VIRVir Biotechnology, Inc.-1144.58% -$1.17 $896.3M VTGNVistagen Therapeutics, Inc.28.3% -$0.54 $68.2M -
What do Analysts Say About VIR or VTGN?
Vir Biotechnology, Inc. has a consensus price target of $17.22, signalling upside risk potential of 164.96%. On the other hand Vistagen Therapeutics, Inc. has an analysts' consensus of $14.50 which suggests that it could grow by 234.87%. Given that Vistagen Therapeutics, Inc. has higher upside potential than Vir Biotechnology, Inc., analysts believe Vistagen Therapeutics, Inc. is more attractive than Vir Biotechnology, Inc..
Company Buy Ratings Hold Ratings Sell Ratings VIRVir Biotechnology, Inc.5 0 0 VTGNVistagen Therapeutics, Inc.4 0 0 -
Is VIR or VTGN More Risky?
Vir Biotechnology, Inc. has a beta of 1.346, which suggesting that the stock is 34.595% more volatile than S&P 500. In comparison Vistagen Therapeutics, Inc. has a beta of 0.561, suggesting its less volatile than the S&P 500 by 43.86%.
-
Which is a Better Dividend Stock VIR or VTGN?
Vir Biotechnology, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vistagen Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Vir Biotechnology, Inc. pays -- of its earnings as a dividend. Vistagen Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios VIR or VTGN?
Vir Biotechnology, Inc. quarterly revenues are $240K, which are smaller than Vistagen Therapeutics, Inc. quarterly revenues of $258K. Vir Biotechnology, Inc.'s net income of -$163.1M is lower than Vistagen Therapeutics, Inc.'s net income of -$19.4M. Notably, Vir Biotechnology, Inc.'s price-to-earnings ratio is -- while Vistagen Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vir Biotechnology, Inc. is 53.17x versus 151.98x for Vistagen Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income VIRVir Biotechnology, Inc.53.17x -- $240K -$163.1M VTGNVistagen Therapeutics, Inc.151.98x -- $258K -$19.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Google Vs NVIDIA Stock: Which Is Best?
Alphabet (NASDAQ:GOOGL) and NVIDIA (NASDAQ:NVIDIA) are two of the market’s…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Buy
56
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
81
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 40x
Alerts
Buy
56
SMX alert for Dec 6
SMX (Security Matters) Plc [SMX] is up 134.09% over the past day.
Buy
62
PRAX alert for Dec 6
Praxis Precision Medicines, Inc. [PRAX] is up 30.47% over the past day.
Sell
13
PSN alert for Dec 6
Parsons Corp. [PSN] is down 21.1% over the past day.
